12,12-Dibromo-11-dodecenoic acid | 206052-04-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 12,12-Dibromo-11-dodecenoic acid
• 英文别名: 12,12-dibromododec-11-enoic acid
• CAS: 206052-04-2
• 化学式: C₁₂H₂₀Br₂O₂
• 分子量: 356.09
• InChiKey: GXKMJMQDIBYOKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES
  申请人：MCW Research Foundation, Incorporated

  公开号：EP2061450A2

  公开（公告）日：2009-05-27
• Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
  申请人：Sweeney William E.

  公开号：US20080167382A1

  公开（公告）日：2008-07-10

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
• Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases
  申请人：Sweeney William E.

  公开号：US20140329811A1

  公开（公告）日：2014-11-06

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
• US8846764B2
  申请人：——

  公开号：US8846764B2

  公开（公告）日：2014-09-30
• US9511072B2
  申请人：——

  公开号：US9511072B2

  公开（公告）日：2016-12-06